73 related articles for article (PubMed ID: 2974747)
41. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics.
Meller E; Bohmaker K; Goldstein M; Friedhoff AJ
J Pharmacol Exp Ther; 1985 Jun; 233(3):656-62. PubMed ID: 2861276
[TBL] [Abstract][Full Text] [Related]
42. In vivo labeling of dopamine receptors: light microscopic localization at the cellular level by means of dipping autoradiography with the agonist (3H)N-n-propylnorapomorphine.
Loopuijt LD; Sebens JB; Korf J
J Neural Transm; 1987; 68(1-2):15-23. PubMed ID: 3806085
[TBL] [Abstract][Full Text] [Related]
43. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.
Hess EJ; Battaglia G; Norman AB; Creese I
Mol Pharmacol; 1987 Jan; 31(1):50-7. PubMed ID: 3100940
[TBL] [Abstract][Full Text] [Related]
44. Downregulation of muscarinic receptors in the rat caudate-putamen after lesioning of the ipsilateral nigrostriatal dopamine pathway with 6-hydroxydopamine (6-OHDA): normalization by fetal mesencephalic transplants.
Dawson TM; Dawson VL; Gage FH; Fisher LJ; Hunt MA; Wamsley JK
Brain Res; 1991 Feb; 540(1-2):145-52. PubMed ID: 1905173
[TBL] [Abstract][Full Text] [Related]
45. Perinatal asphyxia induces long-term changes in dopamine D1, D2, and D3 receptor binding in the rat brain.
Chen Y; Hillefors-Berglund M; Herrera-Marschitz M; Bjelke B; Gross J; Andersson K; von Euler G
Exp Neurol; 1997 Jul; 146(1):74-80. PubMed ID: 9225740
[TBL] [Abstract][Full Text] [Related]
46. Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum.
Enz A; Goldstein M; Meller E
Mol Pharmacol; 1990 Apr; 37(4):560-5. PubMed ID: 1970116
[TBL] [Abstract][Full Text] [Related]
47. Effect of aging on striatal dopamine receptor subtype recovery following N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline blockade and relation to motor function in Wistar rats.
Henry JM; Joseph JA; Kochman K; Roth GS
Brain Res; 1987 Aug; 418(2):334-42. PubMed ID: 2960421
[TBL] [Abstract][Full Text] [Related]
48. Effects of chronic treatment with selective agonists on the subtypes of dopamine receptors.
Subramaniam S; Lucki I; McGonigle P
Brain Res; 1992 Feb; 571(2):313-22. PubMed ID: 1351781
[TBL] [Abstract][Full Text] [Related]
49. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
Graham WC; Sambrook MA; Crossman AR
Brain Res; 1993 Feb; 602(2):290-303. PubMed ID: 8095431
[TBL] [Abstract][Full Text] [Related]
50. Dopamine D2 receptors are present in prefrontal cortical afferents and their targets in patches of the rat caudate-putamen nucleus.
Wang H; Pickel VM
J Comp Neurol; 2002 Jan; 442(4):392-404. PubMed ID: 11793342
[TBL] [Abstract][Full Text] [Related]
51. Differential effects of EEDQ on the dopamine D-1 receptor in vivo and in vitro.
Andersen PH
Eur J Pharmacol; 1988 Jul; 152(1-2):153-6. PubMed ID: 2905267
[TBL] [Abstract][Full Text] [Related]
52. Effect of repeated treatment with antidepressant drugs and electroconvulsive shock (ECS) on the D2 dopaminergic receptor turnover in the rat brain.
Nowak G; Zak J
Pharmacol Toxicol; 1991 Aug; 69(2):87-9. PubMed ID: 1775435
[TBL] [Abstract][Full Text] [Related]
53. Improved high-affinity binding of 3H-apomorphine with a subcellular membrane fraction of mammalian brain tissue.
Arana GW; Baldessarini RJ; Herschel M; Fava M
Life Sci; 1981 Jul; 29(2):121-33. PubMed ID: 6270486
[No Abstract] [Full Text] [Related]
54. Brain receptors for central and peripheral melanotropins.
Tatro JB
Ann N Y Acad Sci; 1993 May; 680():621-5. PubMed ID: 8512232
[No Abstract] [Full Text] [Related]
55. Receptor alkylating agents: novel tools for the study of receptor function in the central nervous system of the rat.
Crocker AD; Cameron DL
Clin Exp Pharmacol Physiol; 1989 Jun; 16(6):545-8. PubMed ID: 2670361
[TBL] [Abstract][Full Text] [Related]
56. Expression of newly cloned brain dopamine receptors in peripheral organs.
O'Connell DP
Biochem Soc Trans; 1996 Feb; 24(1):169-72. PubMed ID: 8674652
[No Abstract] [Full Text] [Related]
57. Regional differences in reappearance of D2-dopamine receptors in the rat caudate-putamen complex after irreversible inactivation.
Loopuijt LD; Sebens JB; Korf J
Brain Res; 1988 Jul; 456(2):263-70. PubMed ID: 2974747
[TBL] [Abstract][Full Text] [Related]
58. Inhibition of substantia nigra dopamine cell firing by R(-)-N-n-propylnorapomorphine: electrophysiological and autoradiographic studies after regional inactivation of dopamine receptors by microinjection of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
Cox RF; Waszczak BL
Brain Res; 1993 Jun; 613(1):32-42. PubMed ID: 8102308
[TBL] [Abstract][Full Text] [Related]
59. Autoradiographic localization and quantification of dopamine D2 receptors in normal human brain with [3H]N-n-propylnorapomorphine.
Camus A; Javoy-Agid F; Dubois A; Scatton B
Brain Res; 1986 Jun; 375(1):135-49. PubMed ID: 3719352
[TBL] [Abstract][Full Text] [Related]
60. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study.
Morissette M; Lévesque D; Di Paolo T
Mol Pharmacol; 1992 Sep; 42(3):480-8. PubMed ID: 1357544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
